62 results
S-3ASR
EX-4.3
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
responsibility for the administration of this Indenture (which, for the avoidance of doubt, includes without limitation any supplemental indenture hereto … have any responsibility or liability for any actions taken or not taken by the Depositary.
Section 2.06 Temporary Securities.
Pending
S-3ASR
EX-4.2
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
because of such person’s knowledge of and familiarity with the particular subject and, in each case, who shall have direct responsibility … to determine substantial compliance as to form with the express requirements hereof.
Neither the Trustee nor any Agent shall have any responsibility
S-3ASR
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity … , and we take no responsibility for any other information that others may give you. If you are in a jurisdiction where offers to sell
PRE 14A
hma2n6f3ko
16 Apr 24
Preliminary proxy
4:30pm
8-K
EX-1.1
5nx2ytr w2
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
424B5
2frwkjj50iew 1dvaw
6 Mar 24
Prospectus supplement for primary offering
5:16pm
424B5
vbhs0bgq3
4 Mar 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-1.1
qvs ahuoagsysl2sieq
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
424B5
uyik4458qcvdbmsa
17 May 23
Prospectus supplement for primary offering
4:45pm
8-K
EX-1.1
c3gq0kcoqfl6vtt76j
16 Sep 22
Entry into a Material Definitive Agreement
4:02pm
424B5
u8mkqva5d aruoq
15 Sep 22
Prospectus supplement for primary offering
5:16pm
424B5
eojmafu1bt
13 Sep 22
Prospectus supplement for primary offering
5:11pm